Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.32%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
-
Rhea-AI Summary
Aceragen, Inc. (Nasdaq: ACGN) announced that its independent Data Monitoring Committee (DMC) recommended the continuation of the TERRA Phase 2 study for ACG-701, targeting melioidosis patients. This recommendation is based on a planned safety review, allowing the trial to proceed without modifications. The TERRA study, which began in May 2022, is a randomized double-blind trial aimed at evaluating ACG-701's effectiveness in severely ill patients. The company has secured a development partnership worth approximately $50 million with the Department of Defense to explore ACG-701 as a medical countermeasure. Data read-out from the study is expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.34%
Tags